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Abstract
Background—LDL that contains apolipoprotein C-III (apoC-III) comprises only 10 to 20% of
plasma LDL, but has a markedly altered metabolism and proatherogenic effects on vascular cells.
Methods and results—We examined the association between plasma LDL with apoC-III and
coronary heart disease (CHD) in 320 women and 419 men initially free of cardiovascular disease
who developed a fatal or non-fatal myocardial infarction during 10 to 14 years of follow-up, and
matched controls who remained free of CHD.
Concentrations of LDL with apoC-III (measured as apoB in this fraction) were associated with
risk of CHD in multivariable analysis that included the total cholesterol to HDL cholesterol ratio,
LDL cholesterol, apolipoprotein B, triglycerides, or HDL cholesterol; and other risk factors. In all
models, the relative risks for the top versus bottom quintile of LDL with apoC-III were greater
than those for LDL without apoC-III. When included in the same multivariable adjusted model,
the risk associated with LDL with apoC-III (relative risk for top versus bottom quintile 2.38, 95
percent confidence interval, 1.54 to 3.68; P for trend <0.001) was significantly greater than that
associated with LDL without apoC-III (relative risk for top versus bottom quintile 1.25, 95 percent
confidence interval, 0.76 to 2.05; P for trend=0.97), P for interaction <0.001. This divergence in
association with CHD persisted even after adjustment for plasma triglycerides.
Conclusions—The risk of CHD contributed by LDL appeared to result to a large extent from
LDL that contains apoC-III.
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VLDL and LDL each are heterogeneous lipoprotein classes that vary in size and content of
lipid and protein (1). ApoB is the required structural apolipoprotein of VLDL and LDL.
Each VLDL and LDL has only one molecule of apoB but may have none or many molecules
of apoC-III attached to its surface (1–3). About 40 to 60% of VLDL and 10–20% of LDL
have apoC-III (2,3). ApoC-III has deleterious effects on the metabolism of VLDL and LDL
(4–6) and on functions of cells that participate in atherosclerosis (7). ApoC-III interferes
with the binding of VLDL to receptors on the liver, and this inhibits the removal of VLDL
from plasma (5,6,8). Nearly all VLDL that has apoC-III undergoes intravascular lipolysis of
its triglyceride content producing LDL with apoC-III, and large-size LDL with apoC-III is
metabolized to small LDL (5,6,9).
ApoC-III-containing VLDL and LDL prepared from human plasma activate monocytes that
circulate in blood to adhere to vascular endothelial cells, an early step in atherosclerosis
(10,11). ApoC-III also activates vascular endothelial cells to produce adhesion molecules
and it induces insulin resistance in these cells reducing their secretion of nitric oxide (12).
These actions are not shared by VLDL or LDL that do not have apoC-III. The presence of
apoC-III on LDL is also associated with compositional changes that favor LDL adhesion to
the subendothelial extracellular matrix (13). Thus, apoC-III may trap its associated
lipoproteins in the arterial wall and bring in blood monocytes, crucial steps in initiation and
progression of atherosclerosis. ApoC-III concentrations in VLDL and LDL are positively
associated with the progression of atherosclerosis or risk of coronary heart disease (14–17),
and we had reported that LDL with apoC-III associates with recurrent cardiovascular disease
among patients with a prior myocardial infarction and type 2 diabetes (3).
To evaluate whether plasma concentrations of VLDL and LDL that have apoC-III, as
measured by apoB in each of them, are more strongly associated with coronary heart disease
(CHD) risk than those of the same lipoproteins without apoC-III, we prospectively studied
two U.S. populations initially free of coronary heart disease (CHD): the Nurses’ Health
Study [NHS] in women and the Health Professionals Follow-up Study [HPFS] in men.
Methods
Study population
The NHS and the HPFS are prospective cohort investigations respectively involving
121,700 female U.S. registered nurses who were 30 to 55 years old at baseline in 1976 and
51,529 U.S. male health professionals who were 40 to 75 years old at baseline in 1986.
Information about health and disease is assessed biennially (18–21).
From 1989 through 1990, a blood sample was requested from all participants in the NHS,
and 32,826 women provided one. Similarly, between 1993 and 1995, a blood sample was
provided as requested by 18,225 men in the HPFS. Participants who provided blood samples
were similar to those who did not. In the NHS, among women without cardiovascular
disease or cancer before 1990, we identified 350 women who had a nonfatal myocardial
infarction or fatal CHD between the date of blood drawing and June 2004. In the HPFS, we
identified 425 men initially free of cardiovascular disease who had a nonfatal myocardial
infarction or fatal CHD between the date of blood drawing and the return of the 2004
questionnaire. Using risk-set sampling (a technique in which in a prospective cohort,
controls are selected among the group of individuals exposed to the studied factor at the time
the event occurs in the case [22]), we randomly selected controls in a 1:1 ratio who were
matched for age (+/− 1 year), smoking status (never, past or current), and date of blood
sampling (+/− 2 months) from the participants who were free of cardiovascular disease at
the time CHD was diagnosed in the case patients. Within the NHS cohort, an additional
matching criterion was fasting status at the time of blood sampling.
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Assessment of coronary heart disease
Study physicians who were unaware of the participant’s exposure status confirmed the
diagnosis of myocardial infarction on the basis of the criteria of the World Health
Organization. Deaths were identified from state vital records and the National Death Index
or reported by the participant’s next of kin or the postal system. Fatal CHD was confirmed
by an examination of hospital or autopsy records, by the listing of CHD as the cause of
death on the death certificate, if CHD was the underlying and most plausible cause, and if
evidence of previous CHD was available.
Assessment of other factors
Medical history, lifestyle, and demographic information was derived from the questionnaire
administered in 1990 to women and 1994 to men, with missing information substituted from
previous questionnaires. Physical activity was expressed in terms of metabolic equivalent
(MET)–hours. The questionnaires and the validity and reproducibility of measurements have
been described previously (18–21).
Measurement of lipids and apolipoproteins levels
Blood samples from women were collected in heparin-treated tubes, and samples from men
in EDTA-treated tubes. The tubes were placed on ice packs, shipped in Styrofoam
containers by overnight courier, centrifuged, divided into aliquots, and stored in liquid-
nitrogen freezers (−130°C or colder). One vial containing 0.6 mL (Nurses’ Health Study) or
0.5 mL (Health Professionals Follow-up Study) of frozen plasma was shipped to the
lipoprotein laboratory at the Harvard School of Public Health for analysis of lipoprotein
types. Study samples were sent to the laboratory for analysis in randomly ordered batches,
and the laboratory personnel were unaware of a sample’s case–control status. The entire
plasma sample was thawed, filtered and incubated overnight with affinity-purified
polyclonal goat anti-human apoC-III antibodies (Academy Biomedical, Houston, TX) bound
to Sepharose 4B resin, as previously described and validated (2,23). The unbound
lipoproteins that did not contain apoC-III were collected by gravity flow, and the bound
lipoproteins that contained apoC-III were eluted with 3M sodium thiocyanate. The
efficiency of the apoCIII immunoaffinity separation (percentage of ligand removed from
plasma by the resin) was 99%. Subsequently, apoCIII-bound and -unbound fractions were
ultracentrifuged to isolate the very low-density (d<1.006 g/mL), low-density
(1.006<d<1.063 g/mL) and high-density (d>1.063 g/mL) lipoproteins (24). Apolipoprotein
B (apoB) and apoC-III were measured in whole plasma and in VLDL and LDL with and
without apoC-III by enzyme-linked immunosorbent assay, and cholesterol and triglycerides
were measured by enzymatic methods (Infinity Kit, Thermo Fischer Scientific, Waltham,
Massachussetts).
In order to test the repeatability of the assays, we ran blinded controls that were sent by the
Channing Laboratory disguised as samples and included in every batch with their own IDs.
These controls were included and ran in every batch of real samples so that each control
went through the whole process at least 8 times. The coefficients of variation were for NHS:
9% for apoB in LDL without apoC-III and 17% for apoB in LDL with apoC-III; and for
HPFS: 17% for apoB in LDL without apoC-III and 13% for apoB in LDL with apoC-III.
The study protocol was approved by the institutional review board of the Brigham and
Women’s Hospital and the Human Subjects Committee Review Board of the Harvard
School of Public Health. After excluding participants with insufficient sample or missing
data for apoB in at least one of the LDL and VLDL fractions, the dataset consisted of 1476
participants (320 female and 419 male cases and 320 female and 419 male controls). The
cases were identified and the controls selected in two-year cycles. Two men selected as
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controls in one cycle later developed CHD and were selected in a subsequent cycle, this time
as cases. For this reason the study sample contains 1476 and not 1478 individuals. For these
two participants we used the same baseline measurements in the pair where they were cases
and in the pair where they were controls.
Because there is only one apoB molecule per lipoprotein particle, the apoB concentration
represents the concentration of lipoproteins of a given type. Our main exposure, specified in
the protocol and according to our previous result (3) was the concentration of LDL with
apoC-III, as reflected by the concentration of apoB in this fraction, i.e. “apoB in LDL with
apoC-III”.
Statistical analysis
Data from the two cohorts were analyzed at the individual-participant level (as opposed to
separate analysis in each cohort plus meta-analysis). Apolipoprotein measurements were
divided into quintiles, from the lowest to highest levels, on the basis of the sex-specific
distributions among the controls. We analyzed the association between apolipoprotein levels
and the risk of CHD using conditional logistic regression. With risk-set sampling, the odds
ratio derived from the logistic regression directly estimates the hazard ratio and, thus, the
relative risk (25). We analyzed our exposures in four logistic models: model one conditioned
on matching factors only, model two with additional adjustment for parental history of CHD
before the age of 60 years, alcohol intake and personal history of hypertension at baseline;
model three with adjustment for all the variables in model two plus body mass index and
personal history of diabetes; and model four adding triglyceride concentration at baseline.
Baseline was defined as the year blood was drawn. To test for linear trend, we used the
median levels of apolipoprotein measurements in the control categories as a continuous
variable.
To test for an interaction between LDL types, we ran a model that included LDL quintile,
presence or absence of apoC-III, and an interaction term.
All P values are two-tailed, and P values below 0.05 were considered to indicate statistical
significance. All analyses were performed with the use of SAS software, version 9.1 (SAS
Institute).
Results
LDL with apoC-III represented on average 12% of total LDL. Participants of both sexes
who developed CHD during follow-up had significantly higher concentrations of LDL with
apoC-III. Male but not female cases had higher concentrations of LDL without apoC-III
than controls (Table 1). Participants in the highest quintile of LDL with apoC-III, as
compared with participants in the lowest quintile, had a significantly increased risk of CHD
(relative risk for highest versus lowest quintile 2.58, 95 percent confidence interval, 1.78 to
3.74, P for trend<0.001), conditioning on matching factors (Table 2). LDL without apoC-III
was associated with CHD but with a lower relative risk than LDL with apoC-III (1.72, 95
percent confidence interval, 1.14 to 2.61). Adjustment for other risk factors in models 2, 3,
and 4, including personal history of diabetes and triglyceride concentration, had little effect
on the relative risks (Table 2). The risk associated with LDL with apoC-III was similar in
NHS and HPFS participants, with no significant sex interaction, but the risk associated with
LDL without apoC-III was higher in HPFS (Supplemental Table 1 and Table 2). It was not
possible to perform multivariate logistic analyses in the diabetic subgroup (n=126) due to its
small size (model did not converge), but among nondiabetic participants (n=1350) the
multivariate adjusted results were consistent with those for the complete study sample
(relative risk for top vs bottom quintile of LDL with apoC-III 2.39, 95% CI: 1.56–3.67).
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Independence of association of LDL with apoC-III from other lipid risk factors
We explored whether the association between LDL with apoC-III and CHD was
independent of other established lipid risk factors. In the background of model 2, we added
LDL cholesterol, HDL cholesterol, plasma apoB, plasma triglycerides, the total cholesterol-
to-HDL cholesterol ratio or non-HDL cholesterol, one-by-one, and in all models LDL with
apoC-III remained significantly associated with CHD (Figure 1). In contrast, LDL without
apoC-III was not significantly independent of LDL cholesterol, plasma triglycerides, the
total cholesterol to HDL cholesterol ratio or non-HDL cholesterol (Supplemental Figure 1).
No effect modification by hypertriglyceridemia
To address the strength of the relationship between LDL with apoCIII and CHD at different
TG levels, first we added a quintile interaction term of [triglycerides*LDL with apoC-III] to
the model, and its coefficient was not significant, p=0.46. Second, we computed the relative
risk for LDL with apo-CIII in the participants who had normal or high TG, according to the
standard cutpoint, 150 mg/dL. The point estimates of the relative risks were similar: 1.61 for
participants with triglycerides<150 mg/dL and 1.77 for participants with triglycerides>=150
mg/dL, p for interaction=0.63. Thus the finding on LDL CIII as an independent predictor of
CHD was not significantly modified by hypertriglyceridemia.
Comparison of LDL with and without apoC-III
When quintiles of LDL with apoC-III and quintiles of LDL without apoC-III were included
in the same multivariable adjusted model (Figure 2, panel A), only LDL with apoC-III was
associated with CHD (relative risk 2.38, 95 percent confidence interval, 1.54 to 3.68;
compared with relative risk 1.25, 95 percent confidence interval 0.76 to 2.05 for LDL
without apoC-III), P for difference in slopes <0.001. Given that apoC-III stimulates hepatic
secretion of triglycerides, we performed additional analyses adding plasma triglycerides to
this model (Figure 2, panel B). The association with CHD was still significantly higher for
LDL with apoC-III (P for difference in slopes=0.001).
We obtained similar results in a model adjusted for the same covariates, in which cholesterol
substituted for apoB. Cholesterol in LDL with apoC-III (relative risk for highest versus
lowest quintile 2.01, 95 percent confidence interval, 1.35 to 2.99), but not cholesterol in
LDL without apoC-III (relative risk for highest versus lowest quintile 1.30, 95 percent
confidence interval, 0.86 to 1.95) was significantly associated with CHD (Supplemental
Figure 2).
Analyses for apoC-III concentrations
The concentration of apoC-III in LDL was associated with CHD after adjustment for risk
factors (Table 2), but the association was less consistent than for the apoB concentration of
LDL with apoC-III (concentration of LDL particles with any apoC-III) (Figure 3). Total
plasma apoC-III was associated with increased risk of CHD (Table 2), but the association
lost significance in model 3 or after addition of any of the major known lipid risk factors to
model 2.
Analyses of VLDL
Concentrations of VLDL with apoC-III and VLDL without apoC-III were associated with
CHD similarly and significantly. Adjustment for body-mass index and diabetes in model 3
attenuated the relative risks for both VLDL types but both were still significant
(Supplemental Table 2).
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Relative size of VLDL and LDL with and without apoC-III
The mean triglyceride:apoB molar ratio, an indicator of VLDL particle size, was higher for
VLDL with apoC-III than for VLDL without apoC-III (11724 vs 7988) in the study sample.
The mean cholesterol:apoB molar ratio, an indicator of LDL particle size, was higher for
LDL with apoC-III than for LDL without apoC-III (2934 vs 2373).
Characteristics associated with a high concentration of LDL with apoC-III
Higher levels of LDL with apoC-III were associated with a markedly higher prevalence of
diabetes, higher plasma triglycerides, lower HDL cholesterol levels, slightly higher body-
mass indexes, and a higher prevalence of hypertension (Supplemental Table 3).
Contrastingly, higher levels of LDL without apoC-III were not associated with any of these
conditions, but with higher LDL cholesterol and plasma apoB.
Analyses excluding statin users
In analyses restricted to the 704 participants who never received cholesterol-lowering
medications during follow-up, and adjusted for all variables in model 2; the relative risk of
CHD for the top versus bottom quintile of LDL with apoC-III was 2.6 (95 percent
confidence interval 0.87 to 7.83; P for trend=0.049).
Use of postmenopausal hormone replacement therapy and LDL types
To explore whether hormone replacement therapy might confound the association between
LDL with apoC-III and CHD, we compared levels of LDL with and without apoC-III among
women who used or did not use hormone replacement. Levels of LDL with apoC-III did not
differ between users and non-users (0.85 mg/dL for users versus 0.81 mg/dL for non-users,
p=0.53). The same was observed for LDL without apoC-III (77.6 mg/dL for users versus
77.5 mg/dL for non-users, p= 0.96).
Discussion
In this prospective study of individuals initially free of cardiovascular disease, the
concentration of LDL that contains apoC-III was robustly associated with CHD significantly
more so than LDL that does not contain apoC-III.
The association between LDL with apoC-III and CHD was linear and persisted after
adjustment for diverse risk factors. In fact, the association was only slightly affected by
adjustment for alcohol use, family history of CHD, diabetes, hypertension or hormone use;
although the study had limited power to address subtle modification. When concentrations
of LDL with apoC-III and LDL without apoC-III were included in the same model, only
LDL with apoC-III was associated with CHD, suggesting that a considerable proportion of
the CHD risk commonly attributed to LDL concentrations is in fact due to one of its sub-
fractions that contains apoC-III. This result extends our previous finding in patients with
pre-existing CHD and type 2 diabetes (3). The sample size of our study, 739 cases, was able
to identify a minimum increased relative risk of 1.4 for either type of LDL. However, it is
possible that a still larger sample size would identify a mild relation between LDL without
apoC-III and CHD.
Besides its effects that impair lipoprotein metabolism and stimulate monocyte adhesion to
vascular endothelial cells, apoC-III may promote the inflammatory process that fuels
atherosclerosis through activation of toll-like-receptor 2 in monocytes (26), and through
induction of insulin resistance and inflammatory signaling pathways governed by nuclear
factor kappa-B in endothelial cells (12,27). Finally, heterozygote carriers of a nonsense
mutation in the apoC-III gene have significantly less coronary artery calcification and CHD
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than noncarrier subjects from the same population (28). All this evidence provides biological
plausibility for a direct involvement of LDL with apoC-III in atherosclerosis.
There are on average 10–20 molecules of apoC-III, but only one molecule of apoB in each
LDL with apoC-III (2). The apoB concentration of LDL with apoC-III was more strongly
associated with CHD than the apoC-III concentration of the same LDL. Thus, the number of
apoC-III molecules per LDL may be less important than the concentration of this type of
LDL. This was not what we found for VLDL, where particles with or without apoC-III were
similarly associated with CHD risk. Thus, the biological effects of apoC-III may be
lipoprotein specific. In this respect, enhancement of LDL adhesion to proteoglycans by
apoC-III depends on a critical site in apoB (13). It is conceivable that this site may only be
exposed in LDL, after most triglycerides in VLDL have been lipolyzed.
Our results suggest only a modest association between total plasma levels of apoC-III and
CHD that was attenuated after adjustment for other lipid risk factors. Plasma apoC-III is a
relatively simple determination in a clinical laboratory, while the measurement of LDL with
apoC-III is more complex and time consuming but seems to provide more meaningful
information.
The association between LDL with apoC-III and CHD was independent of LDL cholesterol,
in agreement with previous evidence showing that plasma VLDL and LDL with apoC-III
predict the progression of atherosclerosis even among patients whose LDL cholesterol is
markedly reduced with lovastatin (29). Thus, LDL with apoC-III may explain part of the
residual CHD risk among individuals without elevated LDL cholesterol.
Our analyses excluding users of cholesterol-lowering drugs at any point during follow-up
showed that among never users, the relative risk estimate for LDL with apoC-III was quite
similar to that in the complete study sample, ruling out confounding by indication of statins.
This result is in accordance with a published analysis of the impact of pravastatin on
concentrations of lipoproteins with and without apoC-III in patients with diabetes from the
CARE trial (30): statin treatment reduced LDL with apoC-III by 29% and LDL without
apoC-III by 30%. Also, all traditional lipid risk factors were associated with CHD in our
study sample (Supplementary Table 4), so the results for LDL with apoC-III do not seem to
be the consequence of an unusual population.
Our indirect estimation of LDL size by the cholesterol:apoB molar ratio showed that LDL
with apoC-III was on average larger than LDL without apoC-III, so it seems unlikely that
LDL with apoC-III is just acting like a proxy for small, dense LDL. ApoC-III has been
reported to transfer from VLDL to HDL during freezing or storage (31). In this regard, we
performed a small experiment in samples from 4 volunteers measuring apoC-III in VLDL,
LDL and HDL immediately after plasma separation and after 5 months of storage at −80
degrees Celsius. The distribution of apoC-III changed only very slightly and
nonsignificantly (from 14% in VLDL, 16% in LDL, 70% in HDL when analyzed fresh; to
12% in VLDL, 15% in LDL, 73% in HDL after freezing/storage/thawing), so we believe
this effect is unlikely to have had an important influence in our results under our sample
handling and preserving procedures. Another potential concern is whether a high
concentration of LDL with apoC-III might just be identifying subjects with
hypertriglyceridemia and mild insulin resistance. Even though there was a significant
correlation between LDL with apoC-III and plasma triglycerides (r=0.42), the association
between CHD and LDL with apoC-III persisted after adjustment for triglycerides,
suggesting that both characteristics may have common origins but are independently
associated with CHD. A limitation of our study is that we did not have baseline
measurements of plasma glucose and insulin that would have permitted a better adjustment
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for carbohydrate metabolism, so we relied on self-reported diagnosis of diabetes. Another
relevant limitation is that we performed multiple statistical tests needed to explore multiple
factors of interest and multiple models per factor. This may have inflated the rate of type I
error above the nominal 5% used per test.
We cannot be certain of whether apoC-III is causally responsible for CHD or a marker for
other properties of certain LDL particles. Human LDL with apoC-III has been found to have
a different lipid composition than LDL without apoC-III (13),that may influence the effect
of LDL with apoC-III on atherosclerosis. Nevertheless, when our results are put together
with the evidence of reduced atherosclerosis in humans with genetically reduced apoC-III
(28) and with the abundant documentation of direct proatherogenic effects of apoC-III (11–
13, 27); these results encourage further research into apoC-III as a potentially causative
factor in atherosclerosis and CVD, and as a target for therapy. Ultimately, even if the
presence of apoC-III is just a label for a type of LDL very strongly associated with CHD, the
existence of a marker for such particles can prove useful in the targeting and optimization of
preventive interventions.
In summary, our results suggest that the concentration of LDL with apoC-III is
independently associated with the risk of CHD, and that much of the risk ordinarily
attributed to LDL may in fact be due to LDL particles that contain apoC-III. These findings
are consistent with prior in vitro, animal and epidemiological evidence suggesting enhanced
atherogenicity of lipoproteins containing apoC-III. More than contributing to the
improvement of already excellent prediction models (32–34), we think that our results may
endorse LDL with apoC-III as a highly attractive target for the prevention or treatment of
atherosclerotic diseases.
During the last few years, evidence has accumulated indicating that the protein
composition of lipoproteins may be more relevant to atherogenesis and cardiovascular
risk than the absolute concentrations of plasma lipids. One of these compositional factors
is apolipoprotein C-III, a small interchangeable apolipoprotein that impairs hepatic
uptake of circulating lipoproteins and has various direct proatherogenic effects on the
arterial wall. In this study, we prospectively analyzed the association between plasma
concentrations of LDL that contains or does not contain apoC-III and the appearance of
coronary heart disease (CHD) events in more than 1400 men and women. Our key
finding was that in a multivariate adjusted model that includes concentrations of both
LDL with apoC-III and LDL without it, only LDL with apoC-III was consistently and
significantly associated with risk, indicating that an important fraction of the
cardiovascular risk traditionally adjudicated to LDL may in fact be due to LDL with
apoC-III. The findings were robust to adjustment for levels of plasma lipids,
demographic cardiovascular risk factors, and to diabetes status. The identification of
LDL with apoCIII as a lipoprotein type disproportionately associated with the
development of CHD adds to the enlarging body of evidence suggesting involvement of
apoC-III in atherogenesis and metabolic derangements, and should stimulate further
research exploring apoC-III as an interventional target in the prevention of CHD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Relative risk of coronary heart disease during follow up in the complete study sample,
according to levels of apoB in LDL with apoC-III, in models including other major lipid risk
factors. Each panel represents a separate model in which apoB and another lipid risk factor
were mutually adjusted. Solid bars represent relative risks for quintile 5 compared to quintile
1 of each risk factor, and error bars represent 95% confidence intervals. All models were
adjusted for matching factors, presence or absence of a parental history of coronary heart
disease before the age of 60 years, alcohol intake and personal history of hypertension.
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Figure 2.
Relative risk of CHD during follow-up in the complete study sample, mutually adjusting
apoB in LDL with and without apoC-III. Relative risks and 95% confidence intervals are
given for each quintile compared to the lowest quintile. In panel A, the model was also
adjusted for matching factors, presence or absence of a parental history of coronary heart
disease before the age of 60 years, alcohol intake and personal history of hypertension. In
panel B, the model was adjusted for all variables in panel A plus personal history of diabetes
and plasma triglycerides.
Dark diamonds represent LDL with apoC-III, p for trend<0.001 in panel A, p for trend=0.07
in panel B. Light squares represent LDL without apoC-III, p for trend=0.97 in panel A, p for
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trend=0.22 in panel B. P<0.001 for difference in slopes in panel A, p=0.001 for difference in
slopes in panel B.
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Figure 3.
Relative risk of coronary heart disease during follow-up, according to the tertile of apoB in
LDL with apoC-III and the tertile of apoC-III in LDL at baseline. Subjects in tertile 1 of
apoB in LDL with apoC-III and tertile 1 of apoC-III in LDL served as the reference group.
The model was also adjusted for matching factors, presence or absence of a parental history
of coronary heart disease before the age of 60 years, alcohol intake, personal history of
hypertension, personal history of diabetes and plasma triglycerides.
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